Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Germany, UK, China - Size and Forecast 2024-2028

Epidermal Growth Factor Receptor (EGFR) Inhibitors Market 2024-2028

The Epidermal Growth Factor Receptor (EGFR) Inhibitors Market size is estimated to grow by USD 8,391.32 million at a CAGR of 9.19% between 2023 and 2028. 

The global epidermal growth factor receptor (EGFR) inhibitors market has witnessed significant advancements in technology and research in recent years. EGFR inhibitors are targeted therapy drugs used in the treatment of various cancers, particularly lung cancer, colorectal cancer, and head and neck cancer. These inhibitors work by blocking the signals that promote cancer cell growth and division. In terms of research, scientists are exploring novel combination therapies involving EGFR inhibitors. Furthermore, researchers are actively studying resistance mechanisms to EGFR inhibitors. Despite the initial success of EGFR inhibitors, resistance often develops over time, leading to disease progression. By understanding the underlying resistance mechanisms, scientists can develop strategies to overcome or prevent resistance and enhance the effectiveness of EGFR inhibitors. Thus, advancements in technology and research are expected to increase the demand for EGFR inhibitors, which will propel the growth of the market in focus during the forecast period. 

Technavio has segmented the market into the distribution channel, indication, and geography 

• The  distribution channel segment is classified into retail pharmacies, hospital pharmacies, and online pharmacies
• The indication  segment is classified into lung cancer, colorectal cancer, breast cancer, and others
• The geography segment includes key regions such as North America, Europe, Asia, and the Rest of World (ROW)

It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historic data from 2017 to 2021, besides analyzing the current market scenario.

What will be the size of the Epidermal Growth Factor Receptor (EGFR) Inhibitors Market During the Forecast Period?

To learn more about this report, Request Free Sample

Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Segmentation by Distribution Channel, Indication and Geography Analysis

Distribution Channel Analysis 

Retail pharmacies segment

The market share growth by the retail pharmacies segment will be significant during the forecast period. Retail pharmacies serve as an important distribution channel for EGFR inhibitors, making these drugs accessible to patients worldwide. Patients can easily obtain their prescribed medications from their local retail pharmacies, ensuring timely and convenient access to treatment. This is particularly important for patients with chronic conditions who require long-term EGFR inhibitor therapy.

Get a glance at the market contribution of various segments View a PDF Sample

The retail pharmacies segment was the largest and was valued at USD 5,284.06 million in 2018. Retail pharmacies also play a vital role in ensuring medication affordability by offering competitive pricing and various insurance coverage options. In addition to dispensing EGFR inhibitors, retail pharmacies provide essential patient support services. Pharmacists can educate patients about the potential side effects and drug interactions associated with EGFR inhibitors, helping patients manage their therapy effectively. They also assist in monitoring treatment progress and can provide valuable advice on adherence and lifestyle modifications. Thus, the above-mentioned advantages are expected to increase the demand for retail pharmacies, which will propel the growth of the retail pharmacies segment in the global epidermal growth factor receptor (EGFR) inhibitors market during the forecast period.

Indication  Analysis 

Lung cancer

Lung cancer is a type of cancer caused by an uncontrollable division of cells in the lungs. The epidermal growth factor receptor (EGFR) inhibitors market currently has four approved drugs for the treatment of NSCLC, and multiple drugs are being studied in the late stages of clinical trials. Most of these pipeline drugs are expected to receive marketing approval during the first half of the forecast period, while the rest are expected to get approval in the second half. Other factors such as the increasing special drug designations, are resulting in the quicker approval of the drugs. Upon approval, these drugs are expected to cater to the huge unmet need in the market, thus contributing to the growth of the segment during the forecast period. As a result, the lung cancer segment is expected to be the fastest-growing segment of the global epidermal growth factor receptor (EGFR) inhibitors market during the forecast period.

Colorectal cancer

Colorectal cancer is a set of cancers that start either in the colon or the rectum. Both colon cancer and rectal cancer are often grouped together due to their multiple similarities. As a result, the drugs are often developed to treat both types of cancer. The growing geriatric population, combined with the increasing advances in the healthcare infrastructure and the changing lifestyle, is expected to contribute to the increasing cases of colorectal cancer. Currently, there are only two EGFR inhibitors, ERBITUX and Vectibix, approved for the treatment of colorectal cancer. The colorectal cancer segment is expected to remain the second-largest segment of the global epidermal growth factor receptor (EGFR) inhibitors market, with the segment witnessing an accelerating growth momentum during the forecast period

Regional Analysis

For more insights about the market share of various regions View PDF Sample now!

North America is estimated to contribute 40% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. In 2023, North America accounted for the highest share of the global epidermal growth factor receptor (EGFR) inhibitors market, primarily due to the heavy sales of approved therapeutics. Factors such as the increasing prevalence of various types of major cancer indications are also contributing to the heavy share of the market in the region. According to the NIH, the new cases of various types of major cancers, such as lung cancer, colorectal cancer, and breast cancer, in the US have increased significantly in recent years. In 2020, an estimated 1.8 million new cases of cancer were diagnosed in the US, and 606,520 people will die from the disease. The strong prevalence of these diseases is expected to be a major driving factor for the epidermal growth factor receptor (EGFR) inhibitors market in North America. The advances in the research have resulted in the launch of novel EGFR inhibitors for the treatment of these indications.

Moreover, factors such as the advanced healthcare infrastructure in the region are leading to the vendors choosing the region to conduct clinical studies, as the region is ideal for overcoming any side effects associated with the treatment during the clinical stages. Other factors such as the special drug designations, are also resulting in a quick approval of these therapies and are expected to contribute to the market growth in the region during the forecast period.

The outbreak of COVID-19 in 2020 severely impacted the epidermal growth factor receptor (EGFR) inhibitors market in North America. However, the initiation of vaccination drives led to the lifting of lockdowns, followed by the rescheduling of patient visits to clinics and the adoption of contactless delivery of EGFR inhibitors, was increased in 2021 and 2022 and it is expected to boost the growth of the regional epidermal growth factor receptor (EGFR) inhibitors market during the forecast period.

Buy Now Full Report and Discover More

Key Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

ASSERTIO HOLDINGS INC.: - The company offers epidermal growth factor receptor inhibitors such as APL 101, an orally bioavailable small molecule C met inhibitor that targets the dysregulation of the C met pathway in multiple tumors.

• Amgen Inc
• AstraZeneca Plc
• Boehringer Ingelheim International GmbH
• Bristol Myers Squibb Co.
• Checkpoint Therapeutics Inc.
• Eli Lilly and Co.
• F. Hoffmann La Roche Ltd.
• Hansoh Pharmaceutical Group Co. Ltd.
• hutchison medipharma ltd.
• Jiangsu Hengrui Pharmaceuticals Co. Ltd.
• Johnson and Johnson
• Novartis AG
• Otsuka Holdings Co. Ltd.
• Pfizer Inc.
• Puma Biotechnology Inc.
• Takeda Pharmaceutical Co. Ltd.
• Apollomics Inc.
• CULLINAN ONCOLOGY INC.
• Lutris Pharma

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Epidermal Growth Factor Receptor (EGFR) Inhibitors Market: Key Drivers, Trends, Challenges, and Customer Landscape

There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. 

Key Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Drivers

The rise in the prevalence of major cancer indications is notably driving the market growth. One of the major drivers of the epidermal growth factor receptor (EGFR) inhibitors market is the increasing prevalence of cancer globally. The prevalence of various types of cancer has increased at a significant rate in recent years, and the epidermal growth factor receptor inhibitors market has witnessed the approval of various novel therapies. In addition, a large share of EGFR inhibitors is approved for some of the major cancer indications, such as lung cancer, breast cancer, and colorectal cancer. These drugs are also being studied for the treatment of various major cancer indications. Factors such as the increasing special drug designations and the proven efficacy of EGFR inhibitors are leading to quicker approval in the clinical stages which has a positive impact on the EGFR inhibitors market growth.

Moreover, the increasing number of drug approvals for the treatment of various cancer indications is expected to capture the huge unmet need, thus adding significant value to the global epidermal growth factor receptor (EGFR) inhibitors market during the forecast period.

Significant Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Trends

The rise in the number of drug pipelines is an emerging trend shaping market growth. One of the major drivers of the growth of the epidermal growth factor receptor (EGFR) inhibitors market in the coming years is expected to be the increasing advances in pipeline drugs. The high efficacy of EGFR inhibitors in the treatment of various oncology indications has attracted various large and medium pharmaceutical vendors in the market to conduct research and develop novel EGFR inhibitors. The pipeline of these inhibitors is growing strongly, with promising therapies in the late stages of clinical trials that are being developed by large pharmaceutical vendors for the treatment of multiple cancer indications. The pipeline witnesses the presence of vendors such as AstraZeneca, Boehringer Ingelheim, Eli Lilly, Roche, and Sanofi, which are known for their strong R&D. 

However, most of the drugs are being studied in the late stages of clinical trials for multiple major cancer indications and are expected to receive marketing approval during the forecast period. The epidermal growth factor receptor inhibitors market is expected to benefit significantly from the launch of these molecules which results in the EGFR inhibitors market expansion. Therefore such factors are expected to add both value and volume growth to the market during the forecast period.

Major Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Challenges

High preference for alternative therapies is a significant challenge hindering the market growth. For a long time, the treatment landscape for major cancer indications was dominated by alternative treatment options such as surgery and radiation therapy. The increasing prevalence of cancer has resulted in an urgent need for pharmaceutical vendors to develop more advanced therapies to treat these indications. As a result, the recent advances in the healthcare infrastructure have resulted in the development of various therapeutics for the treatment of these indications. This has resulted in an increase in the demand for therapeutics due to their ease of administration and the high efficacy of the drugs. The advances in the global oncology therapeutics market also resulted in the launching of various regenerative therapies such as gene therapy, cell therapy, and CAR T-cell therapy.

Currently, only a limited number of these regenerative therapies are approved for oncology indications; however, the strong pipeline for these therapies is expected to further increase the threat of alternative therapies. The curative nature of these regenerative therapies poses a huge threat to the EGFR inhibitors market, and the approval of these therapies is expected to increase the threat, leading to less preference for EGFR inhibitors. Such factors are expected to hinder the market growth during the forecast period. 

Buy Now Full Report and Discover More

Key Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Customer Landscape

Segment Overview

The epidermal growth factor receptor (EGFR) inhibitors market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028. 

• Distribution Channel Outlook (USD Million, 2018 - 2028)
  • Retail pharmacies
  • Hospital pharmacies
  • Online pharmacies

• Indication Outlook (USD Million, 2018 - 2028)
  • Lung cancer
  • Colorectal cancer
  • Breast cancer
  • Others

• Region Outlook (USD Million, 2018 - 2028)
  • North America
    • The U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • Rest of World  (ROW)
    • Brazil 
    • Argentina 
    • Australia

Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Scope
Report Coverage	Details
Page number	174
Base year	2023
Historic period	2018-2022
Forecast period	2024-2028
Growth momentum & CAGR	Accelerate at a CAGR of 9.19%
Market growth 2024-2028	USD 8,391.32 million
Market structure	Fragmented
YoY growth 2023-2024(%)	8.68
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 40%
Key countries	US, Canada, Germany, UK, and China
Competitive landscape	Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks
Key companies profiled	Amgen Inc., ASSERTIO HOLDINGS INC., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Checkpoint Therapeutics Inc., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Hansoh Pharmaceutical Group Co. Ltd., hutchison medipharma ltd., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Johnson and Johnson, Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., Puma Biotechnology Inc., Takeda Pharmaceutical Co. Ltd., Apollomics Inc., CULLINAN ONCOLOGY INC., and Lutris Pharma
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

View Sample PDF at your Fingertips

What are the Key Data Covered in this Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the market between 2024 and 2028
• Precise estimation of the epidermal growth factor receptor (EFGR) inhibitors market size and its contribution of the market in focus to the parent market
• Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
• Companies landscape comparing criticality of inputs and factors of differentiation
• Exclusive Matrix on companies' position and classification
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
• Thorough analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of epidermal growth factor receptor (EGFR) inhibitors market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch